Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer

Liu, Shu-Chih; Yang, Shun‐Fa; Yeh, Kun‐Tu; Yeh, Chung-Min; Chiou, Hui‐Ling; Lee, Ching-Yi; Chou, Ming‐Chih; Hsieh, Yih‐Shou

doi:10.1016/j.cca.2006.02.026

Cited by 47 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, all studies have reported an increase in the MMP-to-TIMP ratio in cancer samples and an association with unfavorable prognostic parameters (54,74,75). Regarding enzymatic activity, increased activity of MMP2, MMP7, and MMP9 proteins have been observed in hormone-related cancers and increased activity associated with a more aggressive phenotype (55,58,64,74,76), consistent with the hypothesized role of these enzymes in cancer progression and invasion.…”

Section: Mmp and Timp Expression In Other Hormonerelated Cancerssupporting

confidence: 76%

“…As with prostate cancer, increased MMP production in breast cancer is generally associated with poor prognostic factors, with some exceptions. Numerous studies done in breast cancer reported increased total MMP2 or MMP9 protein expression to be associated with poor prognostic factors (60)(61)(62)(63)(64)(65)(66). However, two studies have reported evidence for an inverse association with poor prognosis: One study found lower levels of active MMP2 protein to confer a decreased recurrence-free survival in breast cancer patients and an inverse relationship between increasing total pro-MMP2 protein in breast cancer serum with nodal status, grade, and stage (67); the second reported a negative association between tumor grade and pro-MMP2 and pro-MMP9 protein expression in breast cancer patient serum (68).…”

Section: Mmp and Timp Expression In Other Hormonerelated Cancersmentioning

confidence: 99%

See 1 more Smart Citation

The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors

O’Mara

Clements

Spurdle

2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Genome-wide association studies have accelerated the discovery of single nucleotide polymorphisms (SNP) associated with susceptibility to complex diseases, including many malignancies. The matrix metalloproteinase (MMP) family of proteases are involved in many cell processes, most notably the degradation of the extracellular matrix, and differences in gene and protein expression have been reported to be associated with many cancers. Surprisingly, none of the SNPs located within these genes have been identified to be associated with cancer in the genome-wide association studies published to date. This may be in part due to the proportion and the tagging efficiency of MMP SNPs covered by high-throughput genotyping chips. This review will provide an overview of current evidence for MMPs and associated SNPs in endometrial and other hormone-related cancers, to provide justification for the further detailed studies of MMP SNPs as cancer markers. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2352-65)

show abstract

Section: Mmp and Timp Expression In Other Hormonerelated Cancerssupporting

confidence: 76%

Section: Mmp and Timp Expression In Other Hormonerelated Cancersmentioning

confidence: 99%

The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors

O’Mara

Clements

Spurdle

2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Therefore, MMPs and TIMPs are regarded as prospective biological markers for prognosis and drug sensitivity of malignant tumors, while the use of natural and synthetic inhibitors of MMP is assumed to be a promising approach to antitumor therapy. Experimental studies revealed the involvement of MMP in the regulation of invasive, migration, and even proliferative activities of breast cancer and demonstrated the possibility of suppression of tumor dissemination by synthetic MMP inhibitors [6,[11][12][13][14]. The data on the impact of MMP for prognosis and clinical course of breast cancer are still scanty and opinions on the subject vary [5,8,13,15].…”

mentioning

confidence: 96%

Matrix Metalloproteinases 2, 7, and 9 in Tumors and Sera of Patients with Breast Cancer

Катунина

Ермилова

et al. 2011

Bull Exp Biol Med

View full text Add to dashboard Cite

Enzyme immunoassay showed that the content of matrix metalloproteinases (MMP) 2 and 7 in tumors was higher than in the adjacent histologically intact tissue in 91 and 76% patients with breast cancer, respectively, while MMP-9 levels in the tumor and intact tissue were virtually the same. Serum concentrations of MMP-2 and MMP-7 did not correlate with their levels in the tumors, were within the normal range, and virtually did not decrease after removal of the primary tumor. Serum levels of MMP-9 in patients were significantly lower than in the control and increased after surgery in 85% patients. No clear-cut relationship between the studied parameters and clinical morphological prognostic factors of breast cancer was detected.

show abstract

“…Other studies on the association between MMP-2 levels and clinicopathologic factors were not inconsistent. While several studies reported that higher serum levels of MMP-2 were shown in the patients with more advanced tumor stage (26,28,33,34), the others showed lower MMP-2 levels in patients with many poor prognostic factors including advanced tumor stage or grade (27,29,35).…”

Section: Discussionmentioning

confidence: 97%

“…[19][20][21][22][23], whereas few others have suggested inconsistent results (24,25). Although there were several studies on the association between the levels of serum MMP-2 and clinicopathologic factors, the results were inconsistent across the studies (26)(27)(28)(29)(30)(31)(32)(33)(34)(35). So far, only a few studies have investigated the association between MMP-2 levels and breast cancer prognosis (36,37).…”

Section: Introductionmentioning

confidence: 99%

Preoperative Serum Levels of Matrix Metalloproteinase-2 (MMP-2) and Survival of Breast Cancer among Korean Women

Song

Sung

Choi

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Matrix metalloproteinase-2 (MMP-2) has been thought of as a predictor of recurrence or metastasis risk or prognostic markers in cancer. We evaluated whether preoperative serum levels of MMP-2 work as a prognostic biomarker in breast cancer prognosis.Methods: Preoperative serum levels of MMP-2 were measured with ELISA in 303 patients with histologically confirmed breast cancer. The median follow-up time for all patients was 4.24 years. The relationship of MMP-2 to survival was investigated using Cox proportional hazard regression model adjusted for the tumornode-metastasis (TNM) stage and estrogen receptor (ER) status.Results: In the multivariate analysis, disease-free survival (DFS) was worse among patients with the third tertile of MMP-2 level than with the first tertile of MMP-2 level [hazard ratio, 1.80; 95% confidence interval (CI), 1.04-3.11; P ¼ 0.04]. However, when the patients were stratified by age, ER status, histologic grade, and nuclear grade, inverse correlation was shown between serum MMP-2 levels and prognostic factors, and the associations between MMP-2 and DFS were only significant among patients with poor prognostic factors (HR, 2.75; 95% CI, 1.32-5.73 in ER-negative; HR, 2.90; 95% CI, 1.42-5.92 in histologic grade III; and HR, 2.61; 95% CI, 1.26-5.39 in nuclear grade III).Conclusions: Our results suggest that the preoperative serum levels of MMP-2 were associated with the survival in patients with breast cancer in ER-negative, higher histologic grade, or higher nuclear grade breast cancers.Impact: Our results indicate that serum levels of MMP-2 may play a role as prognostic biomarker in breast cancer survival. Cancer Epidemiol Biomarkers Prev; 21(8); 1371-80. Ó2012 AACR.

show abstract

Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer

Cited by 47 publications

References 29 publications

The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors

The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors

Matrix Metalloproteinases 2, 7, and 9 in Tumors and Sera of Patients with Breast Cancer

Preoperative Serum Levels of Matrix Metalloproteinase-2 (MMP-2) and Survival of Breast Cancer among Korean Women

Contact Info

Product

Resources

About